News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TSO3 (TOS) Reports Record Second Quarter 2017 Results



8/2/2017 12:34:53 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

QUEBEC CITY and MYRTLE BEACH, SC, Aug. 1, 2017 /PRNewswire/ - TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, reported financial results for its second fiscal quarter 2017 ended June 30, 2017.

Second Quarter 2017 Financial Summary

  • Revenue increased to $4.6 million, a 10% sequential increase over the $4.2 million recorded in the first quarter of 2017 and a 53% increase over the $3.0 million recorded in the second quarter of 2016. The Company shipped 40 STERIZONE® VP4 Sterilizers to Getinge Infection Control, its exclusive global distributor, in the second quarter of 2017.
  • Gross profit was $1.7 million, or 38% of revenue, which compares gross profit of $1.6 million, or 37% of revenue, in the first quarter of 2017 and a gross profit of $0.8 million, or 28% of revenue, in the second quarter of 2016.
  • Research and Development (R&D) expense grew to $1.5 million, as compared to $1.4 million in the first quarter of 2017 and $0.8 million in the year-ago quarter.
  • Sales, General and Administrative (SG&A) expense was $2.4 million, as compared to $2.2 million in the first quarter of 2017 and $1.5 million in the second quarter of 2016.
  • The Company's net loss was $(2.3) million or $(0.02) per share in the second quarter of 2017 and compares to net losses of $(2.0) million or $(0.02) per share in the first quarter of 2017 and $(1.5) million, or $(0.02) per share, in the second quarter of 2016.
  • The Company had $16.7 million in cash, cash equivalents and investments and no debt as at June 30, 2017, as compared to $19.6 million and no debt at the end of the first quarter of 2017.

Management Commentary

To read full press release, please click here.


Read at BioSpace.com


comments powered by Disqus
TSO3 Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES